dickkopf like acrosomal protein 1Genealiases: CT34 · SGY · SGY-1 · SGY1
Q-omics provides the consensus-scored DKKL1 profile across patient tissues and cancer cell-line models. DKKL1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DKKL1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, DKKL1 RNA expression shows 15,631 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where DKKL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DKKL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DKKL1 survival associations across molecular data types. DKKL1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DKKL1 RNA expression–survival associations across cancer types. High DKKL1 expression shows unfavorable associations in KIRC, LGG, COAD, SCLC and LIHC, but favorable associations in UVM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DKKL1 RNA expression.
This table summarizes DKKL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DKKL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DKKL1 shows lower tumor expression in KIRC and PAAD and higher tumor expression in LIHC, HNSC, LUSC and CHOL. The KIRC box plot shows higher DKKL1 RNA expression in normal versus tumor tissue (log2 FC = −0.251, t-test p < 0.001).
This table shows molecular features associated with DKKL1 in patient tissues and cancer cell lines. In patient samples, DKKL1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DKKL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
